And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is modest for now, but will include promenading with the official mascots, a visit with our remaining Pharmalot ancestor and an afternoon in a nearby park. If time and energy permit, we may indulge with a brief listening party. where the rotation may feature this, this, this, and this. And what about you? This is a lovely time of year to stroll through city streets, along a beach or through the woods. If the greet indoors beckon instead, you could stream a bunch of moving pictures, or you could support your local library and catch up on your reading. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …
Novo Nordisk sued nine more medical spas, wellness clinics, and pharmacies in the U.S. for selling products claiming to contain semaglutide, the key ingredient in its popular weight-loss drug Wegovy, Reuters notes. The drugmaker has now filed 21 lawsuits since June over the sale of copycat versions of semaglutide. Five sellers have been barred from selling their disputed products. One lawsuit has been amended after samples it tested were found to be as much as 33% impure. The latest suits were filed in federal courts in Colorado, Florida, Illinois, Montana, Texas, and Tennessee.
Novartis has filed a lawsuit seeking to block a Maryland law that requires the company to ship its medicines to any pharmacy working with hospitals participating in a controversial U.S. government drug discount program, STAT reports. The drugmaker maintained that the state law, which goes into effect on July 1, improperly forces pharmaceutical companies to supply so-called contract pharmacies as part of the discount program known as 340B, according to the lawsuit filed in federal court. Novartis argued the law is illegal because it is preempted by federal law and also violates the U.S. Constitution.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect